Abstract LBA59
Background
CheckMate 9LA (NCT03215706), a phase III randomized study, met its primary endpoint of improved overall survival with NIVO 360 mg Q3W + IPI 1 mg/kg Q6W + 2 cycles of chemo (n = 361) vs 4 cycles of chemo (n = 358) in patients (pts) with treatment-naive, stage IV/recurrent NSCLC and no known sensitizing EGFR/ALK alterations. We present PROs from the study.
Methods
PROs were exploratory endpoints; disease-related symptoms were evaluated using the Lung Cancer Symptom Scale average symptom burden index and 3-item global index (LCSS ASBI/3-IGI); health-related quality of life (HRQoL) was evaluated using EQ-5D-3L visual analog scale and utility index (EQ-5D-3L VAS/UI). Analyses included mean changes from baseline, mixed-effect model repeated measures (MMRM) of longitudinal changes, and time to deterioration.
Results
PRO completion rates were > 80% across arms for most on-treatment assessment time points in which there were ≥ 10 pts (up to week 90 for NIVO + IPI + chemo and week 78 for chemo). A trend for improvement in LCSS ASBI and 3-IGI was seen in both treatment arms, though the minimally important difference was not reached. In both arms, mean EQ-5D-3L VAS scores approached UK population norms after ∼30 weeks. MMRM analyses showed similar improvement across arms in overall LCSS ASBI when there was a sufficient number of patients in both study arms for assessment (up to week 78). There was a decreased risk of, and delayed time to, definitive deterioration with NIVO + IPI + chemo vs chemo (Table).
Conclusions
Pts with advanced NSCLC treated with NIVO + IPI + chemo (2 cycles) maintained their quality of life as compared with chemo (4 cycles). Pts in the NIVO + IPI + chemo arm had decreased risk of definitive deterioration in HRQoL and symptoms vs chemo. Table: LBA59
Time to deterioration with NIVO + IPI + chemo (2 cycles) vs chemo (4 cycles)
HRa (95% CI) | |
Time to first deteriorationb | |
LCSS ASBI | 1.16 (0.91–1.48) |
LCSS 3-IGI | 1.10 (0.89–1.36) |
EQ-5D-3L VAS | 1.07 (0.88–1.30) |
EQ-5D-3L UId | 0.88 (0.72–1.07) |
Time to definitive deterioration c | |
LCSS ASBI | 0.66 (0.47–0.92) |
LCSS 3-IGI | 0.66 (0.50–0.88) |
EQ-5D-3L VAS | 0.73 (0.58–0.93) |
EQ-5D-3L UId | 0.72 (0.57–0.90) |
Includes on-treatment and follow-up. aHR < 1 favors NIVO + IPI + chemo over chemo. bTime from randomization to when change in PRO score first meets/exceeds deterioration threshold. cIn addition to initial assessment, all subsequent assessments must meet/exceed the threshold. dBased on UK norms.
Clinical trial identification
NCT03215706.
Editorial acknowledgement
Professional writing assistance was provided by Laura Yee, of Caudex, funded by Bristol-Myers Squibb Company.
Legal entity responsible for the study
Bristol-Myers Squibb Company.
Funding
Bristol-Myers Squibb Company.
Disclosure
M. Reck: Advisory/Consultancy, Travel/Accommodation/Expenses: Abbvie; Advisory/Consultancy, Travel/Accommodation/Expenses: Amgen; Advisory/Consultancy, Travel/Accommodation/Expenses, Speaker Bureau/Expert testimony: AstraZeneca; Advisory/Consultancy, Travel/Accommodation/Expenses, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Bristol Myers Squibb; Advisory/Consultancy, Travel/Accommodation/Expenses, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Boehringer-Ingelheim; Advisory/Consultancy, Travel/Accommodation/Expenses, Speaker Bureau/Expert testimony: Lilly; Advisory/Consultancy, Travel/Accommodation/Expenses, Speaker Bureau/Expert testimony: Merck; Advisory/Consultancy, Travel/Accommodation/Expenses, Speaker Bureau/Expert testimony: MSD; Advisory/Consultancy, Travel/Accommodation/Expenses, Speaker Bureau/Expert testimony: Novartis; Advisory/Consultancy, Travel/Accommodation/Expenses, Speaker Bureau/Expert testimony: Pfizer; Advisory/Consultancy, Travel/Accommodation/Expenses, Speaker Bureau/Expert testimony: Roche; Advisory/Consultancy: Samsung. T-E. Ciuleanu: Advisory/Consultancy, Travel/Accommodation/Expenses: Astella Pharma; Advisory/Consultancy, Travel/Accommodation/Expenses: Janssen; Advisory/Consultancy, Travel/Accommodation/Expenses: Bristol Myers Squibb; Advisory/Consultancy, Travel/Accommodation/Expenses: Merck Serono; Advisory/Consultancy, Travel/Accommodation/Expenses: Amgen; Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy, Travel/Accommodation/Expenses: MSD; Advisory/Consultancy, Travel/Accommodation/Expenses: Servier; Advisory/Consultancy, Travel/Accommodation/Expenses: Ipsen; Advisory/Consultancy, Travel/Accommodation/Expenses: AD Pharma; Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca; Advisory/Consultancy, Travel/Accommodation/Expenses: Lilly; Advisory/Consultancy, Travel/Accommodation/Expenses: Novartis. M. Schenker: Research grant/Funding (self, related to the current clinical trial), Research grant/Funding (institution, related to the current clinical trial): Bristol Myers Squibb; Research grant/Funding (self, not related to the current clinical trial), Research grant/Funding (institution, not related to the current clinical trial): MSD; Research grant/Funding (self, not related to the current clinical trial), Research grant/Funding (institution, not related to the current clinical trial): AstraZeneca; Research grant/Funding (self, not related to the current clinical trial), Research grant/Funding (institution, not related to the current clinical trial): Pfizer; Research grant/Funding (self, not related to the current clinical trial), Research grant/Funding (institution, not related to the current clinical trial): Regeneron; Research grant/Funding (self, not related to the current clinical trial), Research grant/Funding (institution, not related to the current clinical trial): Novartis; Research grant/Funding (self, not related to the current clinical trial), Research grant/Funding (institution, not related to the current clinical trial): Roche; Research grant/Funding (self, not related to the current clinical trial), Research grant/Funding (institution, not related to the current clinical trial): Astellas; Research grant/Funding (self, not related to the current clinical trial), Research grant/Funding (institution, not related to the current clinical trial): AbbVie; Research grant/Funding (self, not related to the current clinical trial), Research grant/Funding (institution, not related to the current clinical trial): Bayer; Research grant/Funding (self, not related to the current clinical trial), Research grant/Funding (institution, not related to the current clinical trial): Eli Lilly; Research grant/Funding (self, not related to the current clinical trial), Research grant/Funding (institution, not related to the current clinical trial): Merck Serono; Research grant/Funding (self, not related to the current clinical trial), Research grant/Funding (institution, not related to the current clinical trial): Gilead; Research grant/Funding (self, not related to the current clinical trial), Research grant/Funding (institution, not related to the current clinical trial): Amgen. B. Zurawski: Honoraria (self), Speaker Bureau/Expert testimony: Bayer; Honoraria (self), Speaker Bureau/Expert testimony: Astellas; Honoraria (self), Speaker Bureau/Expert testimony: MSD; Honoraria (self), Speaker Bureau/Expert testimony: Bristol Myers Squibb; Honoraria (self): Janssen Cilag; Honoraria (self): AstraZeneca. J. Bennouna: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy: Bristol Myers Squibb; Honoraria (self), Advisory/Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory/Consultancy: MSD; Honoraria (self), Advisory/Consultancy: Servier; Honoraria (self), Advisory/Consultancy: Bayer. L. Paz-Ares: Honoraria: Adacap; Honoraria: Amgen; Honoraria, Research grant/Funding: AstraZeneca; Honoraria: Bayer; Honoraria, Blueprint Medicines; Honoraria, Boehringer Ingelheim; Honoraria, Research grant/Funding: Bristol Myers Squibb; Honoraria: Celgene; Honoraria: Eli Lilly; Honoraria: Incyte; Honoraria: Ipsen; Honoraria, Research grant/Funding: Merck Sharp and Dohme; Honoraria: Novartis; Honoraria, Research grant/Funding: Pfizer; Honoraria: PharmaMar; Honoraria: Roche; Honoraria: Sanofi; Honoraria: Servier; Honoraria: Sysmex; Honoraria: Takeka; Leadership role: Altum sequencing; Officer/Board of Directors: Genómica. S. Lu: Advisory/Consultancy, Speaker bureau/Expert testimony, Research grant/Funding (self): AstraZeneca; Advisory/Consultancy: Boehringer Ingelheim; Research grant/Funding (self): Bristol Myers Squibb; Research grant/Funding (self): Heng Rui; Advisory/Consultancy, Research grant/Funding (self): Hutchison Medipharma; Advisory/Consultancy: Simcere; Advisory/Consultancy: ZaiLab; Advisory/Consultancy: GenomiCare; Advisory/Consultancy, Speaker bureau/Expert testimony, Research grant/Funding (self): Roche; Speaker bureau/Expert testimony: Hansoh. T. John: Honoraria (self), Advisory/Consultancy: Bristol Myers Squibb; Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy: Roche; Honoraria (self), Advisory/Consultancy: Merck; Honoraria (self), Advisory/Consultancy: MSD; Honoraria (self), Advisory/Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory/Consultancy: Bayer; Advisory/Consultancy: Takeda; Honoraria (institution): Specialised Therapeutics; Honoraria (institution): Pfizer; Honoraria (institution): Novartis. B. Padilla, X. Sun, A. Moisei: Full-time employment: Adelphi Values. J. Yan, Y. Yuan: Full-time employment: Bristol Myers Squibb. S.I. Blum: Full-time employment, Stockholder: Bristol Myers Squibb. D.P. Carbone: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/ Expenses: AstraZeneca; Honoraria (self): Nexus Oncology; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Bristol-Myers Squibb; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: Merck; Advisory/ Consultancy, Travel/Accommodation/Expenses: AbbVie; Leadership role: The Ohio State University; Leadership role: ASCO and AACR; Leadership role: NCI; Leadership role: Eastern Cooperative Oncology Group and the Thoracic Core committees for both the Alliance and ECOG/ACRIN; Leadership role, Past president: International Association for the Study of Lung Cancer (IASLC); Leadership role: Damon Runyon, K08, ASCO, AACR, CDA, LIFE and IDEA; Leadership role, Leader: Vanderbilt CCC’s Host-Tumor Interactions and Thoracic/Head and Neck Programs; Leadership role: Vanderbilt Lung Cancer SPORE, and an NCI U01 consortium; Officer/ Board of Directors: IASLC, LCFA, LUNGevity, ALCMI, Joan’s Legacy Foundation, Lance Armstrong Foundation, Wendy Wyrick Foundation, Wendy Will Case Foundation, Jack Roth Foundation; Full/ Part-time employment, Professor of Medicine: The Ohio State University Comprehensive Cancer Center; Advisory/Consultancy, Travel/Accommodation/Expenses: EMD Serono; Advisory/Consultancy, Travel/Accommodation/Expenses: Inviata; Advisory/Consultancy, Travel/Accommodation/Expenses: Inovio; Advisory/Consultancy, Travel/Accommodation/Expenses: Janssen; Advisory/Consultancy, Travel/Accommodation/Expenses: Loxo Oncology; Advisory/Consultancy, Travel/Accommodation/ Expenses: Merck, Sharp & Dohme; Honoraria (self), Advisory/Consultancy, Travel/ Accommodation/Expenses: Pfizer; Advisory/Consultancy, Travel/Accommodation/Expenses: Roche/ Genentech; Advisory/Consultancy, Travel/Accommodation/Expenses: Takeda Oncology; Advisory/ Consultancy, Travel/Accommodation/Expenses: Trinity; Advisory/Consultancy, Travel/Accommodation/ Expenses: Incyte; Advisory/Consultancy, Travel/Accommodation/Expenses: Kyowa Kirin; Advisory/ Consultancy, Travel/Accommodation/Expenses: Novartis; Advisory/Consultancy, Travel/ Accommodation/Expenses: Gritstone Oncology; Advisory/Consultancy, Travel/Accommodation/Expenses: GlaxoSmithKline; Advisory/Consultancy, Travel/Accommodation/Expenses: Roche China; Advisory/Consultancy, Travel/Accommodation/Expenses: GenePlus; Advisory/Consultancy, Travel/ Accommodation/Expenses: Daiichi Sankyo Inc; Advisory/Consultancy: Seattle Genetics, GI Therapeutics (Intellisphere), Gloria Biosciences. All other authors have declared no conflicts of interest.
Resources from the same session
LBA56 - ORIENT-12: Sintilimab plus gemcitabine and platinum (GP) as first-line (1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC)
Presenter: Caicun Zhou
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA57 - MHC-II antigen presentation pathway as a predictive biomarker for sintilimab plus chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC)
Presenter: Yunpeng Yang
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1260MO - Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial
Presenter: Giuseppe Giaccone
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA58 - ORR in patients receiving nivolumab plus radiotherapy in advanced non-small cell lung cancer: First results from the FORCE trial
Presenter: Farastuk Bozorgmehr
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA60 - ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations
Presenter: Mark Socinski
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA61 - First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions
Presenter: Stephen Liu
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1261MO - Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins)
Presenter: Gregory Riely
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA62 - Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC
Presenter: Helena Yu
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
Open & welcome
Presenter: Natasha Leighl
Session: Mini Oral - NSCLC, metastatic
Resources:
Slides
Webcast
Invited Discussant LBA56, LBA57 and 1260MO
Presenter: Natasha Leighl
Session: Mini Oral - NSCLC, metastatic
Resources:
Slides
Webcast